Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study

被引：2

作者：

Strati, Paolo ^{[1
]}

Champion, Rebecca ^{[2
]}

Coleman, Morton ^{[3
]}

Smith, Sonali M. ^{[4
]}

Venugopal, Parameswaran ^{[5
]}

Martin, Peter ^{[6
]}

Wood, Andrew ^{[7
]}

Miller, Kara ^{[8
]}

Christian, Beth ^{[9
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Norton Canc Inst, Louisville, KY USA

[3] Weill Cornell Med, Clin Res Alliance, New York, NY USA

[4] Univ Chicago, Med Ctr, Chicago, IL USA

[5] Rush Univ, Med Ctr, Chicago, IL USA

[6] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA

[7] AstraZeneca, Cambridge, England

[8] AstraZeneca, South San Francisco, CA USA

[9] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 06期

关键词：

B-cell lymphoma; Bruton tyrosine kinase; non-Hodgkin lymphoma; TYROSINE KINASE INHIBITOR; B-CELLS; IBRUTINIB; ACP-196;

D O I：

10.1111/bjh.19787

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Acalabrutinib is a selective, second-generation Bruton tyrosine kinase inhibitor. In this open-label, parallel-group study, patients with relapsed/refractory (R/R) follicular lymphoma (FL) were randomised to either acalabrutinib monotherapy or acalabrutinib plus rituximab. An additional cohort of patients with treatment-naive (TN) FL received only the acalabrutinib-rituximab combination. Acalabrutinib-rituximab was well tolerated and active in R/R and TN FL; in the TN cohort the overall response rate was 92.3% with most remissions lasting over 4 years. Acalabrutinib monotherapy was also well tolerated and active in R/R FL. These results support further study of acalabrutinib alone and in combination with rituximab in FL.

引用

页码：2248 / 2253

页数：6

共 50 条

[41] Phase II open-label study of sunitinib in patients with advanced breast cancer
Denise A. Yardley
E. Claire Dees
Stephen D. Myers
Sherry Li
Paul Healey
Zhixiao Wang
Marla J. Brickman
Jolanda Paolini
Kenneth A. Kern
Dennis L. Citrin
Breast Cancer Research and Treatment, 2012, 136 : 759 - 767
[42] Phase II open-label study of sunitinib in patients with advanced breast cancer
Yardley, Denise A.
Dees, E. Claire
Myers, Stephen D.
Li, Sherry
Healey, Paul
Wang, Zhixiao
Brickman, Marla J.
Paolini, Jolanda
Kern, Kenneth A.
Citrin, Dennis L.
BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 759 - 767
[43] Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study
Della-Torre, Emanuel
Lanzillotta, Marco
Campochiaro, Corrado
Di-Colo, Giulia
Mancuso, Gaia
Capurso, Gabriele
Falconi, Massimo
Dagna, Lorenzo
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2021, 84 : 63 - 67
[44] Phase Ib Open-Label Study of Loncastuximab Tesirine in Combination With Other Anticancer Agents in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (LOTIS-7)
Hess, Brian
Solh, Melhem
Gandhi, Mitul
Wang, Ying
Qin, Yajuan
Zinzani, Pier Luigi
Collins, Graham
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S419 - S420
[45] Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial
Mcilroy, Graham
Lax, Sian
Gaskell, Charlotte
Jackson, Aimee
Rhodes, Malcolm
Seale, Tania
Fox, Sonia
Hopkins, Lousie
Okosun, Jessica
Barrington, Sally F.
Ringshausen, Ingo
Ramsay, Alan G.
Calaminici, Maria
Linton, Kim
Bishton, Mark
BMC CANCER, 2024, 24 (01)
[46] Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial
Fukano, Reiji
Mori, Tetsuya
Sekimizu, Masahiro
Choi, Ilseung
Kada, Akiko
Saito, Akiko Moriya
Asada, Ryuta
Takeuchi, Kengo
Terauchi, Takashi
Tateishi, Ukihide
Horibe, Keizo
Nagai, Hirokazu
CANCER SCIENCE, 2020, 111 (12) : 4540 - 4547
[47] Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Li, Xueying
Huang, He
Xu, Bing
Guo, Hongqiang
Lin, Yingcheng
Ye, Sheng
Yi, Jiqun
Li, Wenyu
Wu, Xiangyuan
Wang, Wei
Zhang, Hongyu
Xie, Derong
Peng, Jiewen
Cao, Yabing
Pu, Xingxiang
Guo, Chengcheng
Hong, Huangming
Wang, Zhao
Fang, Xiaojie
Zhou, Yong
Lin, Suxia
Liu, Qing
Lin, Tongyu
CANCER RESEARCH AND TREATMENT, 2019, 51 (03): : 919 - 932
[48] Zilovertamab Vedotin (ZV) Alone or in Combination With Nemtabrutinib in Relapsed or Refractory (R/R) Aggressive and Indolent B-Cell Malignancies (waveLINE-006): An Open-Label, Phase 2 Basket Study
Paskiewicz-Kozik, Ewa
Glimelius, Ingrid
Moreira, Claudia
Garrido, Marcelo
Ernst, Daniel
Jurczak, Wojciech
Merryman, Reid
Kim, Won Seog
Ozcan, Muhit
Santoro, Armando
Sawalha, Yazeed
Berkovits, Alejandro
Ren, Yixin
Ogbu, Uzor
Yusuf, Rushdia
Zinzani, Pier Luigi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S483 - S484
[49] Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study)
Aranda, E.
Manzano, J. L.
Rivera, F.
Galan, M.
Valladares-Ayerbes, M.
Pericay, C.
Safont, M. J.
Mendez, M. J.
Irigoyen, A.
Arrivi, A.
Sastre, J.
Diaz-Rubio, E.
ANNALS OF ONCOLOGY, 2012, 23 (07) : 1919 - 1925
[50] A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
Merryman, Reid W.
Redd, Robert A.
Freedman, Arnold S.
Ahn, Inhye E.
Brown, Jennifer R.
Crombie, Jennifer L.
Davids, Matthew S.
Fisher, David C.
Jacobsen, Eric D.
Kim, Austin I.
LaCasce, Ann S.
Ng, Samuel
Odejide, Oreofe O.
Parry, Erin M.
Isufi, Iris
Kline, Justin
Cohen, Jonathon B.
Mehta-Shah, Neha
Bartlett, Nancy L.
Mei, Matthew
Kuntz, Thomas M.
Wolff, Jacquelyn
Rodig, Scott J.
Armand, Philippe
Jacobson, Caron A.
ANNALS OF HEMATOLOGY, 2024, 103 (01) : 185 - 198

← 1 2 3 4 5 →